IM Cannabis Corp. 6-K Filing

From the Filing

0001178913-25-004131.txt : 20251230 0001178913-25-004131.hdr.sgml : 20251230 20251230075202 ACCESSION NUMBER: 0001178913-25-004131 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20251230 FILED AS OF DATE: 20251230 DATE AS OF CHANGE: 20251230 FILER: COMPANY DATA: COMPANY CONFORMED NAME: IM Cannabis Corp. CENTRAL INDEX KEY: 0001792030 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40065 FILM NUMBER: 251611063 BUSINESS ADDRESS: STREET 1: KIBBUTZ GLIL YAM CITY: CENTRAL DISTRICT STATE: L3 ZIP: 4690500 BUSINESS PHONE: 416-256-4202 MAIL ADDRESS: STREET 1: KIBBUTZ GLIL YAM CITY: CENTRAL DISTRICT STATE: L3 ZIP: 4690500 6-K 1 zk2534143.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934   For the month of December 2025 (Report No. 2)   Commission File Number: 001-40065 IM Cannabis Corp. (Exact Name of Registrant as Specified in Charter) Kibbutz Glil Yam, Central District, Israel 4690500 (Address of principal executive offices)   Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.   Form 20-F ☒      Form 40-F ☐   CONTENTS   On December 30, 2025, the Company issued a press release titled “IM Cannabis Explores U.S. Market Entry Following President Trump’s Executive Order on Increasing Medical Marijuana and Cannabidiol Research,” a copy of which is furnished as Exhibit 99.1 with this Report of Foreign Private Issuer on Form 6-K (this “Report”).   This Report is incorporated by reference into the Company’s Registration Statements on Form F-3 (File No. 333-289571 and 333-288346 ) filed with the Securities and Exchange Commission to be a part thereof from the date on which this Report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.   EXHIBIT INDEX   Exhibit No.   99.1 Press Release dated December 30, 2025 titled “IM Cannabis Explores U.S. Market Entry Following President Trump’s Executive Order on Increasing Medical Marijuana and Cannabidiol Research”.   SIGNATURE   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.     IM CANNABIS CORP.           Date: December 30, 2025 By: /s/ Oren Shuster   Name: Oren Shuster   Title: Chief Executive Officer and Director EX-99.1 2 exhibit_99-1.htm EXHIBIT 99.1 Exhibit 99.1 IM Cannabis Explores U.S. Market Entry Following President Trump's Executive Order on Increasing Medical Marijuana and Cannabidiol Research Engages Exclusive Financial Advisors for U.S. Opportunities and Potential Divestitures of German and Israeli Operations; TORONTO and GLIL YAM, Israel, December 30, 2025 - IM Cannabis Corp. (“ IMC ” or the “ Company ”) (Nasdaq: IMCC), medical cannabis company with operations in Israel and Germany, today announced that it is actively evaluating certain strategic opportunities to expand its operations into the United States cannabis market. This initiative follows President Donald Trump's executive order signed on December 18, 2025, which directs the Attorney General to expedite the rescheduling of marijuana from Schedule I to Schedule III under the Controlled Substances Act, recognizing its medical benefits while maintaining federal oversight. To advance its U.S. entry strategy and assess potential divestitures of its businesses in Germany and Israel, the